A Caltech Library Service

Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain

Verma, Rati and Peters, Noel R. and D'Onofrio, Mariapina and Tochtrop, Gregory P. and Sakamoto, Kathleen M. and Varadan, Ranjani and Zhang, Mingsheng and Coffino, Philip and Fushman, David and Deshaies, Raymond J. and King, Randall W. (2004) Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain. Science, 306 (5693). pp. 117-120. ISSN 0036-8075.

PDF (Materials and Methods, Figs. S1 to S8, Table S1) - Supplemental Material
See Usage Policy.

[img] PDF - Erratum
See Usage Policy.


Use this Persistent URL to link to this item:


To identify previously unknown small molecules that inhibit cell cycle machinery, we performed a chemical genetic screen in Xenopus extracts. One class of inhibitors, termed ubistatins, blocked cell cycle progression by inhibiting cyclin B proteolysis and inhibited degradation of ubiquitinated Sic1 by purified proteasomes. Ubistatins blocked the binding of ubiquitinated substrates to the proteasome by targeting the ubiquitin-ubiquitin interface of Lys^(48)-linked chains. The same interface is recognized by ubiquitin-chain receptors of the proteasome, indicating that ubistatins act by disrupting a critical protein-protein interaction in the ubiquitin-proteasome system.

Item Type:Article
Related URLs:
URLURL TypeDescription DOIArticle Information
Sakamoto, Kathleen M.0000-0003-0494-8838
Deshaies, Raymond J.0000-0002-3671-9354
Additional Information:© 2004 American Association for the Advancement of Science. 1 June 2004; accepted 6 August 2004. We thank the Developmental Therapeutics Program, National Cancer Institute, for providing access to compound collections, C. Pickart for tetraubiquitin chains of defined linkages, A. Salic for recombinant Axin and β-catenin-luciferase, and C. Sawyers for ARGFP. G.T. is supported by NIH National Research Service Award GM068276. K.M.S. is supported by a UCLA Specialized Programs of Research Excellence in Prostate Cancer Development Research Seed Grant (P50 CA92131), U.S. Department of Defense (DAMD17-03- 1-0220), and NIH (R21CA108545). P.C. is supported by NIH R01 GM-45335. D.F. is supported by NIH grant GM65334. R.J.D. is supported by HHMI and the Susan G. Komen Breast Cancer Foundation (DISS0201703). R.W.K. is supported by the NIH (CA78048 and GM66492), the McKenzie Family Foundation, and the Harvard-Armenise Foundation and is a Damon Runyon Scholar. Screening facilities at the Harvard Institute of Chemistry and Cell Biology were supported by grants from the Keck Foundation, Merck and Company, and Merck KGaA. R.J.D. is a founder and paid consultant of Proteolix, which is negotiating with Caltech and Harvard to license a patent related to ubistatin. Molecular interaction data have been deposited in the Biomolecular Interaction Network Database with accession codes 151787 to 151791.
Funding AgencyGrant Number
UCLA Specialized Programs of Research Excellence in Prostate Cancer Development Research Seed GrantP50 CA92131
Department of DefenseDAMD17-03-1-0220
NIHR01 GM-45335
Howard Hughes Medical Institute (HHMI)UNSPECIFIED
Susan G. Komen Breast Cancer FoundationDISS0201703
McKenzie Family FoundationUNSPECIFIED
Harvard-Armenise FoundationUNSPECIFIED
Damon Runyon ScholarUNSPECIFIED
W. M. Keck FoundationUNSPECIFIED
Merck and CompanyUNSPECIFIED
Issue or Number:5693
Record Number:CaltechAUTHORS:20141119-110723281
Persistent URL:
Official Citation:Verma, R., Peters, N. R., D'Onofrio, M., Tochtrop, G. P., Sakamoto, K. M., Varadan, R., . . . King, R. W. (2004). Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain. Science, 306(5693), 117-120. doi: 10.1126/science.1100946
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:51961
Deposited By: Jason Perez
Deposited On:19 Nov 2014 20:48
Last Modified:03 Oct 2019 07:37

Repository Staff Only: item control page